Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: Results from Korean National Health Insurance claims data

Seung Min Jung, Seung Ki Kwok, Ji Hyeon Ju, Yong Beom Park, Sung Hwan Park

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/Aims: Inhibition of tumor necrosis factor (TNF) is an effective treatment for rheumatoid arthritis (RA), but safety concerns about malignancy remain. The aim of this study was to evaluate cancer risk in RA patients treated with TNF inhibitors (TNFi), based on Korean Nationwide Health Insurance claims data. Methods: Patients with seropositive RA were selected from the health insurance database containing all citizens’ medical information, based on both RA diagnosis codes and medications. Between 2010 and 2014, RA patients treated with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and TNFi were enrolled and followed up. We compared the cancer incidence between patients treated with TNFi and csDMARDs using incidence rate ratios (IRRs) after adjustment for age, gender, and observational periods. Results: Of 45,423 selected patients with seropositive RA, 2,337 were treated with TNFi and 43,086 were treated with csDMARDs. The TNFi group was younger and was followed-up for a longer duration. During the observational period, 1,732 and 49 cases of cancer were detected in patients treated with csDMARDs and TNFi, respectively. Old age and male sex were associated with cancer occurrence. Adjusted IRRs for all cancers and common cancers demonstrated that cancer incidence did not differ significantly between the TNFi group and csDMARDs group (IRR = 0.913 for all cancers, p = 0.546). Conclusions: This study revealed that cancer incidence was similar in RA patients treated with TNFi and csDMARDs. Anti-TNF therapy may be a safe therapeutic option for RA treatment, in terms of malignancy.

Original languageEnglish
Pages (from-to)669-677
Number of pages9
JournalKorean Journal of Internal Medicine
Volume34
Issue number3
DOIs
Publication statusPublished - 2019 May

Fingerprint

National Health Programs
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Antirheumatic Agents
Neoplasms
Incidence
Therapeutics
Health Insurance
Databases
Safety

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

@article{6903ff5aebbc4e96acdcfaca9b3d65ca,
title = "Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: Results from Korean National Health Insurance claims data",
abstract = "Background/Aims: Inhibition of tumor necrosis factor (TNF) is an effective treatment for rheumatoid arthritis (RA), but safety concerns about malignancy remain. The aim of this study was to evaluate cancer risk in RA patients treated with TNF inhibitors (TNFi), based on Korean Nationwide Health Insurance claims data. Methods: Patients with seropositive RA were selected from the health insurance database containing all citizens’ medical information, based on both RA diagnosis codes and medications. Between 2010 and 2014, RA patients treated with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and TNFi were enrolled and followed up. We compared the cancer incidence between patients treated with TNFi and csDMARDs using incidence rate ratios (IRRs) after adjustment for age, gender, and observational periods. Results: Of 45,423 selected patients with seropositive RA, 2,337 were treated with TNFi and 43,086 were treated with csDMARDs. The TNFi group was younger and was followed-up for a longer duration. During the observational period, 1,732 and 49 cases of cancer were detected in patients treated with csDMARDs and TNFi, respectively. Old age and male sex were associated with cancer occurrence. Adjusted IRRs for all cancers and common cancers demonstrated that cancer incidence did not differ significantly between the TNFi group and csDMARDs group (IRR = 0.913 for all cancers, p = 0.546). Conclusions: This study revealed that cancer incidence was similar in RA patients treated with TNFi and csDMARDs. Anti-TNF therapy may be a safe therapeutic option for RA treatment, in terms of malignancy.",
author = "Jung, {Seung Min} and Kwok, {Seung Ki} and Ju, {Ji Hyeon} and Park, {Yong Beom} and Park, {Sung Hwan}",
year = "2019",
month = "5",
doi = "10.3904/kjim.2016.374",
language = "English",
volume = "34",
pages = "669--677",
journal = "Korean Journal of Internal Medicine",
issn = "1226-3303",
publisher = "Korean Association of Internal Medicine",
number = "3",

}

Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy : Results from Korean National Health Insurance claims data. / Jung, Seung Min; Kwok, Seung Ki; Ju, Ji Hyeon; Park, Yong Beom; Park, Sung Hwan.

In: Korean Journal of Internal Medicine, Vol. 34, No. 3, 05.2019, p. 669-677.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy

T2 - Results from Korean National Health Insurance claims data

AU - Jung, Seung Min

AU - Kwok, Seung Ki

AU - Ju, Ji Hyeon

AU - Park, Yong Beom

AU - Park, Sung Hwan

PY - 2019/5

Y1 - 2019/5

N2 - Background/Aims: Inhibition of tumor necrosis factor (TNF) is an effective treatment for rheumatoid arthritis (RA), but safety concerns about malignancy remain. The aim of this study was to evaluate cancer risk in RA patients treated with TNF inhibitors (TNFi), based on Korean Nationwide Health Insurance claims data. Methods: Patients with seropositive RA were selected from the health insurance database containing all citizens’ medical information, based on both RA diagnosis codes and medications. Between 2010 and 2014, RA patients treated with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and TNFi were enrolled and followed up. We compared the cancer incidence between patients treated with TNFi and csDMARDs using incidence rate ratios (IRRs) after adjustment for age, gender, and observational periods. Results: Of 45,423 selected patients with seropositive RA, 2,337 were treated with TNFi and 43,086 were treated with csDMARDs. The TNFi group was younger and was followed-up for a longer duration. During the observational period, 1,732 and 49 cases of cancer were detected in patients treated with csDMARDs and TNFi, respectively. Old age and male sex were associated with cancer occurrence. Adjusted IRRs for all cancers and common cancers demonstrated that cancer incidence did not differ significantly between the TNFi group and csDMARDs group (IRR = 0.913 for all cancers, p = 0.546). Conclusions: This study revealed that cancer incidence was similar in RA patients treated with TNFi and csDMARDs. Anti-TNF therapy may be a safe therapeutic option for RA treatment, in terms of malignancy.

AB - Background/Aims: Inhibition of tumor necrosis factor (TNF) is an effective treatment for rheumatoid arthritis (RA), but safety concerns about malignancy remain. The aim of this study was to evaluate cancer risk in RA patients treated with TNF inhibitors (TNFi), based on Korean Nationwide Health Insurance claims data. Methods: Patients with seropositive RA were selected from the health insurance database containing all citizens’ medical information, based on both RA diagnosis codes and medications. Between 2010 and 2014, RA patients treated with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and TNFi were enrolled and followed up. We compared the cancer incidence between patients treated with TNFi and csDMARDs using incidence rate ratios (IRRs) after adjustment for age, gender, and observational periods. Results: Of 45,423 selected patients with seropositive RA, 2,337 were treated with TNFi and 43,086 were treated with csDMARDs. The TNFi group was younger and was followed-up for a longer duration. During the observational period, 1,732 and 49 cases of cancer were detected in patients treated with csDMARDs and TNFi, respectively. Old age and male sex were associated with cancer occurrence. Adjusted IRRs for all cancers and common cancers demonstrated that cancer incidence did not differ significantly between the TNFi group and csDMARDs group (IRR = 0.913 for all cancers, p = 0.546). Conclusions: This study revealed that cancer incidence was similar in RA patients treated with TNFi and csDMARDs. Anti-TNF therapy may be a safe therapeutic option for RA treatment, in terms of malignancy.

UR - http://www.scopus.com/inward/record.url?scp=85064056926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064056926&partnerID=8YFLogxK

U2 - 10.3904/kjim.2016.374

DO - 10.3904/kjim.2016.374

M3 - Article

C2 - 29172405

AN - SCOPUS:85064056926

VL - 34

SP - 669

EP - 677

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

SN - 1226-3303

IS - 3

ER -